Hookipa Pharma Overview
- Year Founded
-
2011
- Status
-
Public
- Employees
-
124
- Stock Symbol
-
HOOK
- Share Price
-
$2.51
- (As of Friday Closing)
Hookipa Pharma General Information
Description
HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies.
Contact Information
Website
www.hookipapharma.comCorporate Office
- 350 Fifth Avenue
- Room Suit 7240
- New York, NY 10118
- United States
Corporate Office
- 350 Fifth Avenue
- Room Suit 7240
- New York, NY 10118
- United States
Hookipa Pharma Stock Performance
As of 06-Dec-2024, Hookipa Pharma’s stock price is $2.51. Its current market cap is $30.3M with 12.1M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.51 | $2.45 | $2.08 - $11.30 | $30.3M | 12.1M | 46.3K | -$3.67 |
Hookipa Pharma Financials Summary
As of 30-Sep-2024, Hookipa Pharma has a trailing 12-month revenue of $50M.
|
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | (20,417) | (6,180) | (31,750) | 76,864 |
| Revenue | 49,999 | 20,129 | 14,249 | 18,448 |
| EBITDA | (44,278) | (82,636) | (62,029) | (70,153) |
| Net Income | (43,371) | (81,580) | (64,915) | (75,665) |
| Total Assets | 109,730 | 161,337 | 170,454 | 126,045 |
| Total Debt | 2,825 | 6,559 | 6,503 | 10,625 |
Hookipa Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Hookipa Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Hookipa Pharma Comparisons
Industry
Financing
Details
Hookipa Pharma Competitors (109)
One of Hookipa Pharma’s 109 competitors is Replimune, a Formerly VC-backed company based in Woburn, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Replimune | Formerly VC-backed | Woburn, MA | ||||
| Ayala Pharmaceuticals | Corporation | Wilmington, DE | ||||
| NexImmune | Formerly VC-backed | Gaithersburg, MD | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| Corvus Pharmaceuticals | Formerly VC-backed | Burlingame, CA |
Hookipa Pharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Hookipa Pharma Patents
Hookipa Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3236106-A1 | Modified arenavirus particles expressing mutant kras, mutated cancer driver gene, or tumor-associated antigen as cancer immunotherapies | Pending | 08-Nov-2021 | ||
| AU-2022381821-A1 | Modified arenavirus particles expressing mutant kras, mutated cancer driver gene, or tumor-associated antigen as cancer immunotherapies | Pending | 08-Nov-2021 | ||
| EP-4429698-A1 | Modified arenavirus particles expressing mutant kras, mutated cancer driver gene, or tumor-associated antigen as cancer immunotherapies | Pending | 08-Nov-2021 | ||
| EP-4337320-A1 | Arenaviruses as vectors | Pending | 13-May-2021 | ||
| US-20240229073-A1 | Arenaviruses as vectors | Pending | 13-May-2021 | C12N15/86 |
Hookipa Pharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Hookipa Pharma Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Hookipa Pharma ESG
Risk Overview
Risk Rating
Updated July, 12, 2022
35.21 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,638
Rank
Percentile
Pharmaceuticals
Industry
of 1,008
Rank
Percentile
Pharmaceuticals
Subindustry
of 473
Rank
Percentile
Hookipa Pharma FAQs
-
When was Hookipa Pharma founded?
Hookipa Pharma was founded in 2011.
-
Where is Hookipa Pharma headquartered?
Hookipa Pharma is headquartered in New York, NY.
-
What is the size of Hookipa Pharma?
Hookipa Pharma has 124 total employees.
-
What industry is Hookipa Pharma in?
Hookipa Pharma’s primary industry is Biotechnology.
-
Is Hookipa Pharma a private or public company?
Hookipa Pharma is a Public company.
-
What is Hookipa Pharma’s stock symbol?
The ticker symbol for Hookipa Pharma is HOOK.
-
What is the current stock price of Hookipa Pharma?
As of 06-Dec-2024 the stock price of Hookipa Pharma is $2.51.
-
What is the current market cap of Hookipa Pharma?
The current market capitalization of Hookipa Pharma is $30.3M.
-
What is Hookipa Pharma’s current revenue?
The trailing twelve month revenue for Hookipa Pharma is $50M.
-
Who are Hookipa Pharma’s competitors?
Replimune, Ayala Pharmaceuticals, NexImmune, Kite Pharma, and Corvus Pharmaceuticals are some of the 109 competitors of Hookipa Pharma.
-
What is Hookipa Pharma’s annual earnings per share (EPS)?
Hookipa Pharma’s EPS for 12 months was -$3.67.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
